NCT00704080View on ClinicalTrials.gov

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

February 29, 2012

Study Completion Date

February 28, 2013

Conditions
Mixed GliomasMalignant GliomasGlioblastoma Multiforme
Interventions
DRUG

XL765 (SAR245409)

Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing

DRUG

Temozolomide

Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days

Trial Locations (6)

10021

Investigational Site Number, New York

14642

Investigational Site Number, Rochester

35205

Investigational Site Number, Birmingham

44195

Investigational Site Number, Cleveland

90024

Investigational Site Number, Los Angeles

02115

Investigational Site Number, Boston

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY